XML 39 R23.htm IDEA: XBRL DOCUMENT v2.4.1.9
Going Concern (Details Narrative) (USD $)
3 Months Ended 116 Months Ended
Mar. 31, 2015
Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Non-cash gain upon deconsolidation ofEntest Biomedical, Inc.   $ 41,645,688us-gaap_OtherNoncashIncome
Net Losses   19,377,575us-gaap_OtherComprehensiveIncomeOtherNetOfTax
Equity in Net Losses of Entest Biomedical, Inc.   663,649us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss
Proceeds from issuance of convertible debt $ 775,000us-gaap_ProceedsFromConvertibleDebt